KRAS and cancer: Indeed, inhibiting KRAS’s enzymatic function of hydrolyzing GTP to GDP would prevent transitioning from its ‘on’ to ‘off’ state and would thus be counter-productive to interrupting the increased signaling seen in this pathway in a cancer setting.